Почетна › Метастатски карцином › Florida › Miami
Kliničke studije za Метастатски карцином u gradu Miami, FL
22 studija za Метастатски карцином traži učesnike na lokacijama u gradu Miami i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Тражи се учесникФаза 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Тражи се учесникФаза 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Тражи се учесникФаза 2
- Sylvester Comprehensive Cancer Center, Miami
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Тражи се учесникФаза 3
- Miami Cancer Institute, Miami
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Тражи се учесникФаза 1/2
- University of Miami; Sylvester Cancer Center, Miami
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Тражи се учесникФаза 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Тражи се учесникФаза 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Miami Cancer Institute at Baptist Health, Inc., Miami
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
Тражи се учесникФаза 3
- University of Miami, Miami
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Тражи се учесникФаза 1
- Sylvester Comprehensive Cancer Center, Miami
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Тражи се учесникФаза 1
- Sylvester Comprehensive Cancer Center, Miami
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Тражи се учесникФаза 3
- Research Site, Miami
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Тражи се учесникФаза 1/2
- Sylvester Comprehensive Cancer Center - Miami, Miami
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Тражи се учесникФаза 3
- University Of Miami-SCCC-Miami, Miami
- University of Miami_SCCC - Kendall, Miami
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Тражи се учесникФаза 3
- Research Site, Miami
- Research Site, Miami
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Тражи се учесникФаза 3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Тражи се учесникФаза 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Тражи се учесникФаза 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Тражи се учесникФаза 1
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Miami
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1
- University of Miami, Miami
Studije za Метастатски карцином u drugim gradovima
- Houston, TX100 студија
- New York City, NY93 студија
- Nashville, TN69 студија
- Boston, MA61 студија
- Los Angeles, CA57 студија
- Arlington, VA52 студија
- St. Louis, MO52 студија
- San Antonio, TX44 студија
- Washington, DC44 студија
- Dallas, TX44 студија
- Philadelphia, PA42 студија
- Chicago, IL42 студија
Ostale studije u gradu Miami
- Рак дојке42 студија
- Рак (све врсте)36 студија
- Немалоклетни карцином плућа35 студија
- Рак простате30 студија
- Гојазност28 студија
- Рак јајника24 студија
- Akutna mijeloidna leukemija24 студија
- Гојазност23 студија
- Многи мијелом22 студија
- Рак плућа22 студија
- Алцхајмерова болест21 студија
- ХОБП20 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.